Chimerix, Inc. (NASDAQ:CMRX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Monday.
According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “
Separately, ValuEngine upgraded shares of Chimerix from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 11th.
Chimerix (CMRX) opened at $4.34 on Monday. Chimerix has a one year low of $4.17 and a one year high of $6.64.
Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.06. The company had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $0.81 million. Chimerix had a negative net margin of 1,440.67% and a negative return on equity of 26.00%. sell-side analysts predict that Chimerix will post -1.6 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Chimerix, Inc. (CMRX) Stock Rating Lowered by Zacks Investment Research” was published by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://transcriptdaily.com/2017/11/15/chimerix-inc-cmrx-stock-rating-lowered-by-zacks-investment-research.html.
Institutional investors have recently made changes to their positions in the stock. Metropolitan Life Insurance Co. NY bought a new position in Chimerix in the 1st quarter worth about $226,000. Dimensional Fund Advisors LP lifted its stake in Chimerix by 114.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,043,336 shares of the biopharmaceutical company’s stock valued at $6,656,000 after acquiring an additional 557,927 shares during the period. Geode Capital Management LLC lifted its stake in Chimerix by 11.7% during the 1st quarter. Geode Capital Management LLC now owns 341,238 shares of the biopharmaceutical company’s stock valued at $2,177,000 after acquiring an additional 35,752 shares during the period. AXA lifted its stake in Chimerix by 284.9% during the 2nd quarter. AXA now owns 258,573 shares of the biopharmaceutical company’s stock valued at $1,409,000 after acquiring an additional 191,400 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in Chimerix by 7.0% during the 1st quarter. Bank of New York Mellon Corp now owns 245,080 shares of the biopharmaceutical company’s stock valued at $1,564,000 after acquiring an additional 16,117 shares during the period. Institutional investors own 67.77% of the company’s stock.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.